Management of Parkinson’s Disease 20 Years from Now: Towards Digital Health Pathways

Current best medical treatment for patients with Parkinson’s disease (PD) involves a medical professional who applies state-of-the-art knowledge of diagnostics and treatment— as derived from cohort studies and clinical trials— to the healthcare process of individual patients. Thus, the much-needed personalization of medicine depends on the abilities, experience and intuition of medical professionals to adjust group-based knowledge to individual decision making. Within 20 years from now, such personal clinical decisions will be largely supported by digital means, also defining a new ecosystem of healthcare often referred to as “digital medicine”. We expect that the next phase of digitalization will include new “digital health pathways”: data-driven personalized decision support that is based on a combination of multimodal data sources, including evidence-based medical knowledge (e.g., clinical guidelines), personal disease profiles (including genetic determinants of disease progression and treatment response), insights into individual disease trajectories (thereby defining subgroups of patients) and individual patients’ needs. Here, we illustrate the potential of this development by sketching the contours of a digitally supported care pathway for gait disability and falls. Such digital health pathways will support the introduction of personalized medicine for PD patients, allowing patients to benefit optimally from individually tailored treatments. This should result in a better quality of life for patients and lower costs for society.

[1]  C. Hansen,et al.  How Mobile Health Technology and Electronic Health Records Will Change Care of Patients with Parkinson’s Disease , 2018, Journal of Parkinson's disease.

[2]  R. Balling,et al.  The Luxembourg Parkinson’s Study: A Comprehensive Approach for Stratification and Early Diagnosis , 2018, Front. Aging Neurosci..

[3]  D. Berg,et al.  Patient's perception: shorter and more severe prodromal phase in GBA‐associated PD , 2018, European journal of neurology.

[4]  Zacharias Kohl,et al.  Sensor-based gait analysis of individualized improvement during apomorphine titration in Parkinson’s disease , 2018, Journal of Neurology.

[5]  Eric J. Topol,et al.  Digital medicine, on its way to being just plain medicine , 2018, npj Digital Medicine.

[6]  Samuel J. Reinfelder,et al.  Wearable sensors objectively measure gait parameters in Parkinson’s disease , 2017, PloS one.

[7]  B. Bloem,et al.  Moving Parkinson care to the home , 2016, Movement disorders : official journal of the Movement Disorder Society.

[8]  Max A. Little,et al.  Technology in Parkinson's disease: Challenges and opportunities , 2016, Movement disorders : official journal of the Movement Disorder Society.

[9]  Max A. Little,et al.  Large-Scale Wearable Sensor Deployment in Parkinson’s Patients: The Parkinson@Home Study Protocol , 2016, JMIR research protocols.

[10]  C. Plewnia,et al.  Alpha‐synuclein gene variants may predict neurostimulation outcome , 2016, Movement disorders : official journal of the Movement Disorder Society.

[11]  Björn Eskofier,et al.  Guest Editorial: Enabling Technologies for Parkinson's Disease Management , 2015, IEEE J. Biomed. Health Informatics.

[12]  Karl E. Friedl,et al.  What Engineering Technology Could Do for Quality of Life in Parkinson's Disease: A Review of Current Needs and Opportunities , 2015, IEEE Journal of Biomedical and Health Informatics.

[13]  Björn Eskofier,et al.  An Emerging Era in the Management of Parkinson's Disease: Wearable Technologies and the Internet of Things , 2015, IEEE Journal of Biomedical and Health Informatics.

[14]  Tejal Patel,et al.  Parkinson’s disease guidelines for pharmacists , 2014, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[15]  G. Deuschl,et al.  Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.

[16]  J. Unützer,et al.  A web-delivered care management and patient self-management program for recurrent depression: a randomized trial. , 2012, Psychiatric services.

[17]  E. James,et al.  The Effects of Clinical Pathways on Professional Practice, Patient Outcomes, Length of Stay, and Hospital Costs , 2012, Evaluation & the health professions.

[18]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[19]  O. Suchowersky,et al.  Treatment of Non‐Motor Symptoms of Parkinson Disease , 2010 .

[20]  R. Califf,et al.  Scientific evidence underlying the ACC/AHA clinical practice guidelines. , 2009, JAMA.

[21]  H. Campbell,et al.  Integrated care pathways , 1998, BMJ.